BPC June 28 updates: ANTH CYAD ESPR fall on disappointing updates. EGLT Advisory Committee Meeting August 4 + updates for ACRX BLRX CHRS EARS INFI ITCI KTOV MRNS NDRM RARE XNCR XOMA

Jun 29, 2016 No Comments by

Updates to the Company Pipeline Database for June 28, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ACRX 2.50 ARX-04 Moderate-to-severe acute pain Phase 3 Phase 3 top-line data due 3Q 2016, with potential NDA filing by end of 2016 ANTH 3.07 Blisibimod Lupus Phase 3 Missed primary endpoints in […]

Daily News Read more

BPC June 27 updates: MRNS data due TODAY. RGLS tumbles on news of clinical hold. AAAP PDUFA date set for December 26 + updates for PBYI MDCO TBRA

Jun 27, 2016 No Comments by

Updates to the Company Pipeline Database for June 27, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary AAAP 27.77 Lutathera Inoperable progressive midgut NETs PDUFA priority review PDUFA date under priority review December 28, 2016 MDCO 33.28 CARBAVANCE Complicated urinary tract infections (cUTI) NDA Filing Phase 3 data met endpoints […]

Daily News Read more

BPC June 23 updates: INNL Phase 3 data due 3Q or early 4Q. ARGL Phase 2 prelim data due June 30 + CAPR CERU RETA

Jun 24, 2016 No Comments by

Updates to the Company Pipeline Database for June 23, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ARQL 1.92 ARQ 087 intrahepatic cholangiocarcinoma (iCCA) Phase 2 Phase 2 preliminary data due June 30, 2016 at ESMO 18th World Congress on Gastrointestinal Cancer CAPR 4.38 CAP-1002 HOPE-Duchenne Duchenne Muscular Dystrophy (DMD) […]

Daily News Read more

BPC June 22 updates: ARDX Phase 2b ESRD data timeline extended to 1Q 2017. ADMS FDA filing due 2016 + updates for INCY AGEN EPZM

Jun 23, 2016 No Comments

Updates to the Company Pipeline Database for June 22, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ADMS 16.39 ADS-5102 – EASE LID trial Levodopa-Induced Dyskinesia NDA filing Phase 3 data released December 2015. NDA filing due 2016 AGEN 4.05 INCAGN1876 Solid tumors – cancer Phase 1/2 Phase 1/2 trial […]

Read more

BPC June 22 updates: GWPH to initiate Phase 3 Infantile spasms trial 4Q + CTRV PBMD PRQR updates

Jun 22, 2016 No Comments

Updates to the Company Pipeline Database for June 21, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary CTRV 0.97 CMX157 Hepatitis B Phase 2 Phase 2 dosing initiated June 2016. Trial to be completed 4Q 2016 GWPH 87.76 Epidiolex Infantile spasms (IS) Phase 3 Phase 3 to be initiated 4Q […]

Read more

BPC June 20 updates: OPK receives swift FDA Approval + updates for EPZM FATE GBT OPHT RDHL SGMO TBPH VICL

Jun 21, 2016 No Comments

Updates to the Company Pipeline Database for June 20, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary EPZM 10.96 Tazemetostat Relapsed or refractory B-cell NHL cancer Phase 2 Phase 2 update at the American Society of Hematology (ASH) Meeting on Lymphoma Biology – June 18 2016 FATE 2.00 ProHema Adult […]

Read more

BPC June 17 updates: ARIA initiates rolling NDA. KURA added to database + SMMT EARS MDGN updates

Jun 18, 2016 No Comments

Updates to the Company Pipeline Database for June 17, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary EARS 4.14 AM-111 HEALOS/ASSENT Acute inner ear hearing loss Phase 3 Commenced HEALOS (EU) trial in November 2015.ASSENT trial (US) commenced June 2016. HEALOS data due 2H 2017 MDGN 5.98 NFC-1 – SAGA […]

Read more

BPC June 16 updates: PRTK spikes up 23% after hours following Phase 3 data. SUPN PDUFA delay + updates for AERI BLPH CCXI CRBP KPTI ONCS

Jun 17, 2016 No Comments

Updates to the Company Pipeline Database for June 16, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AERI 18.51 Rhopressa Glaucoma NDA filing NDA filing due 3Q 2016 BLPH 1.98 INOpulse delivery device Pulmonary Arterial Hypertension (PAH) Phase 3 Phase 3 commenced enrolment June 2016 CCXI 4.80 CCX168 Associated vasculitis […]

Read more

BPC June 15 updates: ENDP Adcom scheduled for fall + FLKS initiates Phase 2 MS trial + CTIX update.

Jun 16, 2016 No Comments

Updates to the Company Pipeline Database for June 15, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ENDP 16.82 OPANA ER Management of pain PDUFA Advisory Committee Meeting planned for fall of 2016. PDUFA July 29 2016 will not be met. FLKS 11.22 FLX-787 Multiple Sclerosis Phase 2 Phase 2 […]

Read more